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ABSTRACT—Background: The small molecule pifithrin-m reversibility inhibits the mitochondrial pathway of apoptosis. The
neuronal effects of pifithrin-m applied after cardiac arrest are unknown. We hypothesized that pifithrin-m reduces neuronal
damage in the most vulnerable brain region, the hippocampus, after cardiac arrest.Methods: In two randomized controlled
serieswe administered pifithrin-m or control in 109 rats resuscitated after 8 or 10min of cardiac arrest. Neuronal damagewas
blindly assessed with histology (Fluoro Jade B: FJB, cresyl violet: CV) in the most vulnerable brain region (CA1 segment of
hippocampus) and with a series of neurobehavioral tests (Open Field Task, Tape-Removal Test, Morris Water Maze test).
Mixed ANOVA was used to combine both series, simple comparisons were done with t tests or Mann–Whitney U test.
Results: Pifithrin-m reduced the number of degenerating, FJB-positive neurons by 25% (mixed ANOVA p group¼0.014).
This was more prominent after 8 min cardiac arrest (8min arrest pifithrin-m 9447 vs control 12837; n¼11 each; 10 min
arrest pifithrin-m 7844, n¼15 vs control 10131, n¼18; p group* arrest length interaction¼0.622). The reduction of
ischemic CV-positive neurons in pifithrin-m animals was not significant (ANOVA p group¼0.063). No significant group
differences were found in neurobehavioral testing. Conclusion: Temporarily inhibition of apoptosis with pifithrin-m after
cardiac arrest decreases the number of injured neurons in the CA1 segment of hippocampus in a cardiac arrest rat model,
without clinical correlate. Further studies should elucidate the role of this neuroprotective agent in different settings and with
longer cardiac arrest.
KEYWORDS—Apoptosis, cardiac arrest, cardiopulmonary resuscitation, hypoxia-ischemia brain, neuroprotection,
pifithrin-m (¼ 2-phenylacetylenesulfonamide), rats
ABBREVIATIONS—CA-1—Cornu Ammonis 1 segment of the hippocampus; CV—cresyl violet; DMSO—dimethylsulfoxide;
FJB—Fluoro-Jade B; IQR—interquartile range; PBS—phosphate buffered saline; ROSC—return of spontaneous
circulation
INTRODUCTION
Cardiac arrest affects more than 300,000 persons annually
alone in the United States (1, 2) and is the most important cause
of global cerebral ischemia. Only a minority of resuscitated
patients is discharged in good neurological condition (3, 4).
Global cerebral ischemia does not necessarily lead to
immediate neuronal death, but initiates the apoptotic cascade,
which results in neurodegeneration (5). This late neuronal
degeneration may open a window of opportunity to mitigate
the devastating effects of ischemia on the brain.
Delayed cell death and apoptosis following stress is directed
by the tumor-suppressor gene-product p53 (6, 7). Transgenic
mice with definitive suppression of p53 ultimately develop
cancer, but suppression of p53 might have short-term advan-
tages. Some studies have found promising effects, e.g., mice
with reduced p53 activity survive otherwise lethal irradiation
(8). Inhibition of p53 restores spontaneous locomotion of the
animals after experimental stroke (9), protects neonatal rat
brain from hypoxic-ischemic injury (10), and attenuates auto-
phagic and apoptotic cell death in the cortex and hippocampus
when given before cardiac arrest in rats (11).
The effect of blocking the p53 pathway after global ischemic-
reperfusion injury induced by cardiac arrest is unknown. We
assessed the feasibility and effect of a single dose of the anti-
apoptotic small molecule pifithrin-m given after cardiac arrest of
either 8 or 10 min. We hypothesized that pifithrin-m reduces the
numbers of degenerated cells in the most vulnerable part of the
brain, the hippocampus Cornu Ammonis 1 (CA-1) segment, and
improves outcome measured with neurobehavioral testing.
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MATERIALS AND METHODS
The study included two series: randomized open label allocation of pifithrin
(PIF) or placebo (C) following return of spontaneous circulation (ROSC) after 8
min of cardiac arrest (n¼ 74) and evaluation of brain histology by a blinded
assessor and neurobehavioral testing on day 1 (n¼ 23) or 5 (n¼ 22) or
neurobehavioral testing with a Moris Water Maze starting at day 10–14
(n¼ 23). Additional six rats were used as controls for brain histology
(Fig. 1). Randomized blinded allocation of PIF or C following ROSC after
10 min of cardiac arrest (n¼ 40), and brain histology and neurobehavioral
testing on day 5 (Fig. 2A).The rational for the stepwise approachwas to limit the
number of used animals and to implement possible variations of the protocol
(e.g., duration of cardiac arrest).
All animal studies were approved by the Animal Care and Experimentation
Committee of the Canton of Bern, Switzerland (BE 55/13 and BE 16/15) and
followed the Swiss national guidelines for the performance of animal exper-
iments. Adult maleWistar rats (9–10 weeks old, Janvier Labs, Le Genest-Saint-
Isle, France) were housed at the central animal facilities of the University of
Bern with a 12/12 h light/dark cycle at 228C and food and water ad libitum.
Randomization was done using concealed lots (sealed envelopes), in series 1
before anesthesia and in series 2 after return of spontaneous circulation. In case
of failure of ROSC in series 1, the experiment was repeated immediately.
Anesthesia, instrumentation, cardiac arrest/resuscitation, and postoperative care
were standardized (12) and summarized in the Supplemental Digital Content,
http://links.lww.com/SHK/A595. Briefly, after anesthesia induction, an endo-
tracheal tube and arterial and venous catheters were inserted. Temperature was
managed using an adjustable temperature plate for cooling/heating, and an
infrared bulb. Cardiac arrest was induced with iv-injection of potassium and
esmolol (0.125mmol potassium and 9.375mg esmolol per animal (correspond-
ing to 0.363mmol/kg body weight potassium and 27.3 mg/kg body weight
esmolol)). Resuscitation was performed 8 min (series 1) or 10 min (series 2)
later with ventilation with 100% oxygen, cardiac massage by two fingers at a
metronome-guided frequency of 220-min, and administration of epinephrine and
calcium. Five minutes after ROSC, the study medication in series 1 was given
intraperitoneally [pifithrin-m (Selleck Chemicals, via LuBioScience, Lucerne,
Switzerland, substance for non-human use only) dissolved in 4% dimethylsulf-
oxide (DMSO) in phosphate buffered saline (vehicle) to a final concentration of
0.8 g/L; dose 8mg pifithrin-m per kg]. In series 2, a precision syringe driver
infused the study medication or matching vehicle at a rate of 1mL/h for 4 h
[pifithrin-m dissolved in 96% ethanol (10mg/mL, vehicle) and after random-
ization further diluted in Ringer’s solution (12mg pifithrin-m per kg containing
1.2 mL ethanol 96% diluted to 4 mL]. The animals were euthanized according
to the group allocation at day 1, 5 or after days 10 to 14 with 150mg/kg
pentobarbital intraperitoneally. For brain histology, 150 mL iced normal saline
was infused transcardially via the left ventricle before brain removal. The brain
was post-fixed in buffered formalin [4% in phosphate buffered saline (PBS)] for
24 h at 48C and then transferred to an 18% sucrose solution in PBS at 48C until
further processing.
Cryo-sections were obtained by cutting the brain in 10 and 45mm thick
coronal sections using a Leica CM 1850 cryostat, after snap freezing of the
tissue in methylbutane precooled at 808C.
Fluoro-Jade B (FJB) staining was performed to assess the extent of neuronal
damage on representative slides of the CA1 segment, the only structure with
consistent damage after resuscitation from cardiac arrest (13). Fluorescence
pictures of the hippocampus were recorded with a Zeiss fluorescence micro-
scope (Axiolmager M4, Zeiss, Germany) equipped with a digital camera
(Axiocam HRC) at a 100-fold magnification with mosaic reconstruction of
individual captures using AxioVision software. The software Image J (Rasband,
W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Md, http://imagej.
nih.gov/ij/, 1997–2011) was used to determine the length (inmm) of the CA1
structure under investigation and to count all FJB þ cells in this structure.
Fluoro-Jade results were therefore expressed by normalizing the total amount of
positive cells by the length of the investigated CA1.
The slices were also stained for Nissl substance with cresyl violet (CV). The
percentage of cells with signs of ischemic damage (shrunken appearance and
condensed nucleus) was estimated in the CA1 region by visual observation
under a bright-field microscope of three slides representing the dorsal (septal)
part of the hippocampus.
The histopathology was assessed in both series by the same expert (DG),
who was blinded to the treatment and clinical data. In series 1 only the
FIG. 1. Flow chart of the number of animals assigned into the
different groups of series 1. Six animals were assigned to a sham group
before randomization for laboratory standardization purposes and quality
control. These animals were not analyzed. The remaining 74 rats were
randomized before resuscitation to treatment group and to observation period
(1, 5, and > 10 days). >10 days refers to the animals that were tested in the
watermaze after wound healing, starting the watermaze trial between days 10
and 14. Animals that could not be resuscitated were replaced immediately
replaced with an animal from the same group and duration.
FIG. 2. Left: flow chart of the number of animals assigned into the different groups of series 2. Right: survival analysis of the animals in series 2.
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histopathologic examiner was blinded, whereas in series 2 the whole research
team was blinded to treatment allocation.
We assessed general health (including death) daily until the end of the
experiment, and weight and neurological function daily from baseline (pre-
arrest) until day 5 with an established wide-ranging neuroscore (NDS) (14).
Further neurobehavioral tests performed were an Open Field Task (15), the
Tape-Removal Test (16) in the series 1, and a standard Morris Water Maze test
(17) performed after wound healing (starting day 10 to day 14) in the series 1.
Details of the tests are described in the ESM.
The data was tested for normality with the Shapiro–Wilk test, normal data
were presented as meanSD, non-normal as medians and interquartile ranges
(IQR). Repeated assessments were compared in each experiment separately
with a mixed ANOVA in normally distributed data with post-hoc tests corrected
with Bonferroni method. Non-normal data distribution precluded ANOVA, so
we compared baseline measurements with the Mann–Whitney U test and the
development within each group with the Friedman test. All non-parametric tests
are indicated in Italics. Simple comparisons were performed using parametric
(t test) or non-parametric statistics (Mann–Whitney U test) accordingly.
Kaplan–Meier Survival Analysis (Log-Rank Test) was performed on series
2 only since therewas only one animal that died after ROSC and treatment in the
first series. Results of pathologic-anatomic examinations of both series were
combined with a 2-way ANOVA (factor 1: group [pifithrin or control], factor 2:
experiment [nr 1: 8min cardiac arrest or 2: 10min cardiac arrest]). This 2-way
ANOVA was done once with the absolute cell count (numbers of damaged
neurons), and once where the cell count of the damaged neurons in the PIF
group was normalized to the respective cell count of the C group (100%). A
P< 0.05 was considered significant. Calculations were performed using
SigmaPlot/SigmaStat 12.3 (Systat Software GmbH, Erkrath, Germany).
RESULTS
In experiment 1, 69 of the 74 randomized animals could be
successfully resuscitated (93%). One rat from the pifithrin
group died on day 2 (for details see Fig. 1). In experiment
2, 40 of the 42 animals could be resuscitated (95%). Six animals
died within one day (group PIF n¼ 2; group C n¼ 4) and one
control animal was euthanatized on day 3 because of failure to
thrive and weight loss (Group PIF vs C Kaplan–Meier Survival
Analysis [Log Rank Test] P¼ 0.22). Altogether, 51 rats treated
with pifithrin-m and 50 control animals could be analyzed.
Baseline characteristics of all animals in terms of tempera-
ture, hemodynamic, and respiratory parameters as well as
glucose and lactate variables did not differ between groups
(see Supplemental Digital Content tables suppl 1a þ 1b and
suppl 2, http://links.lww.com/SHK/A595). Time from start of
resuscitation to ROSC did not significantly differ between the
groups (8min cardiac arrest: PIF 86 s [73–100], C 76 s [71–
95], P¼ 0.40; 10min cardiac arrest: PIF 55 s [46–64], C 59 s
[45–65], P¼ 0.61). Doses of adrenaline and calcium did not
differ between groups (details see Supplemental Digital Con-
tent tables suppl 3, http://links.lww.com/SHK/A595), but adre-
naline dose was significantly lower in the Series 2 because of
the shorter time to ROSC.
There were no differences between groups in the trends of
temperature, parameters of the aBGA (pH, pO2, pCO2), lactate
and glucose (for details see Supplemental Digital Content
tables suppl 1a þ 1b and suppl. 2, http://links.lww.com/
SHK/A595), even though the animals developed a significant
lactic acidosis after cardiac arrest with consecutive changes in
pH. The same is true for hemodynamic parameters, where
only changes over time were noted, but no differences between
groups.
Pathologic-anatomic examination with FJB staining at day 5
showed a reduction of damaged neurons in both series 1 (8min
cardiac arrest, PIF: 94 46.9 vs C: 128 36.6, P¼ 0.084) and
series 2 (10min cardiac arrest, PIF: 78 43.7 vs C: 101 31.0,
P¼ 0.095). These results demonstrated a robust and significant
reduction of neuronal damage by 25% (2-way ANOVA of
absolute cell count, group: P¼ 0.014, experiment: P¼ 0.064,
no interaction; 2-way ANOVA of cell count normalized to
100%, group: P¼ 0.019, experiment: P¼ 0.850, no inter-
action), see Table 1 and Figure 3. In the CV staining, results
followed the same trend, but did not reach significance, see
Table 2.
In series 1, the histologic examinations performed on
animals at Day 1 demonstrated only very few damaged
neurons, the numbers were too low to perform statistics on
them (see Supplemental Digital Content table suppl. 4, http://
links.lww.com/SHK/A595). The sectional CA1 area decreased
between Day 1 and Day 5 in all animals (PIF P¼ 0.011, C
P< 0.001), with significant reduced shrinking of the CA1 cell
layer as an indirect marker of reduced neuronal damage in the
Pifithrin-m group (mixed ANOVA, p group: 0.425, P
time:< 0.001, p for interaction:<0.001, details see table suppl.
5, http://links.lww.com/SHK/A595). The 3 non-ischemic sham
animals, euthanatized at day 5, did not depict any signs of
neuronal damage (table suppl. 6, http://links.lww.com/SHK/
A595).
On the part of the general health and other neurobehavioral
tests, no significant differences were observed in weight evol-
ution, where all animals regained and surpassed their baseline
weight. The Neuro Deficit Score was not sensitive enough to
detect a difference compared to baseline beyond Day 2 in both
groups. In the Tape Removal Test both groups returned to
baseline levels after 5 days. In the open field the pifithrin-
treated rats tended to be more mobile and to move longer
distances, but without a significant difference (details see table
suppl 7 aþb, http://links.lww.com/SHK/A595). The Morris
Water Maze Tests (table supple 7a, http://links.lww.com/
TABLE 1. Neuronal damage: histomorphometry of the hippocampus CA1 segment on day 5 with Fluoro-Jade
Variable Series Pifithrin Control Post-hoc
t test
ANOVA
Fluoro-Jade [numbers of stained cells/mm] Series 1 [8min cardiac arrest] 9446.9 12836.6 P: 0.084 p group: 0.014 p exp.: 0.064
p group  exp: 0.622
Series 2 [10min cardiac arrest 7843.7 10131.0 P: 0.095
Fluoro-Jade [normalized to control¼100%] Series 1 [8min cardiac arrest] 7336.6 10028.5 P: 0.084 p group: 0.019 p exp.: 0.850
p group  exp: 0.850
Series 2 [10min cardiac arrest] 7743.3 10031.7 P: 0.095
Fluoro-Jade is a marker for degenerating neurons. The stained CA1 segment of the rat’s hippocampus was examined and results are given in absolute
cell counts per mm CA1 (top), and as percentage in relation to the control group (¼100%, bottom) (numbers are mean standard deviation).
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SHK/A595) demonstrate a better learning capacity in the
mean proximity to virtual platform (p group: 0.436, P time:
<0.001, p group  time: 0.016), the other parameters (time
to first crossing and time in platform quadrant) are not signifi-
cantly different.
DISCUSSION
The main finding of our study is that after cardiac arrest
temporary inhibition of the p53 mediated mitochondrial path-
way of apoptosis with pifithrin-m decreases neuronal damage in
the most vulnerable structure of the brain, the hippocampus
CA1 segment, by 25%.
The p53 protein and its products have a central role in
apoptosis (18). In unstressed cells, p53 remains at low cyto-
plasmatic concentrations. Following different stressors, p53 is
upregulated and exerts pro-apoptotic activity via transcription
of Bcl-2-family proteins in the nucleus (19), and through a
mitochondrial pathway (6, 20). Dysfunctional p53 can be found
in a wide range of cancer cells (21), but p53 is also involved in
delayed cell death after traumatic brain injury (22), stroke (20),
and contributes to side effects of anti-cancer drugs and irradia-
tion. Inhibition of p53 by either drugs or gene knockout leads to
improved survival after irradiation (8, 23), anti-cancer treat-
ment (10, 24), neuronal ischemia (9, 10, 20, 25), myocardial
ischemia (26), and oxidative stress in hepatoma cell lines (27).
The small molecule pifithrin-a inhibits the transcription-
dependent p53, whereas pifithrin-m suppresses the p53 binding
to the mitochondrial membrane (27). Targeting the mitochon-
drial pathway of p53 with pifithrin-m compared to inhibition of
transcription with pifithrin-a increases neuronal protection
(10). In this experiment, Nijboer et al. (10) demonstrated
efficacy of pifithrin-m in a neonatal unilateral ischemia and
hypoxia rat model with small group sizes (n< 10). In their
experiment, inhibition of apoptosis was accounted for the
effect. Recently, Ciu et al. (11) confirmed the apoptotic (and
autophagic) pathways and their subsequent inhibition with
pifithrin-a in an asphyxial cardiac arrest model. In these
experiments the rats were given pifithrin intracisternally before
cardiac arrest, a model that differs in many aspects from ours. In
our experiment we cannot prove the reduction of neuronal
injury is caused by less apoptosis since we have not used a
FIG. 3. Representative pictures of the hippocampus where the green fluorescent neurons demonstrate degeneration. The right histological images
(C and D) show a cardiac arrest animal, contra to the left (A and B), which depicts a sham animal, which did not undergo cardiac arrest and resuscitation. Overview
of the whole hippocampal structures (B and D) is provided, while higher magnification (A and C) shows degenerating neurons in the CA1 segment.
TABLE 2. Neuronal damage: histomorphometry of the hippocampus CA1 segment on day 5 with Cresy Violett
Variable Series Pifithrin Control Post-hoc
t test
ANOVA
Pyknotic cells in CA1 [%] Series 1 [8min cardiac arrest] 2516.7 3921.4 P: 0.111 p group: 0.118 p exp.: 0.039
p group  exp.: 0.830
Series 2 [10min cardiac arrest] 4328.8 5326.3 P: 0.321
Pyknotic cells [normalized to control¼100%] Series 1 [8min cardiac arrest] 6543.3 10055.5 P: 0.111 p group: 0.063 p exp.: 0.552
p group  time: 0.552
Series 2 [10min cardiac arrest] 8154.3 10049.5 P: 0.321
Pyknotic appearing cells determine apoptosis. The stained CA1 segment of the rat’s hippocampus was examined and results are given in absolute cell
counts per mm CA1 (top), and as percentage in relation to the control group (¼100%, bottom) (numbers are mean standard deviation).
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specific apoptosis staining (e.g., caspase 3 or TUNEL). Given
the absence of injury on day one, and in similar experiments on
day 2 (28), we assume that the observed degeneration on day 5
is due to the activation of the intrinsic apoptotic pathway.
Damage of the dorso-septal pole of the hippocampus in rats
results in impaired spatial learning and memory. Unfortunately,
we could not detect group differences in the neurobehavioral
tests. Our functional tests revealed important, albeit not sus-
tained, functional impairment after cardiac arrest. E.g., the time
to remove the tapes in the Tape Removal Test returned to
baseline at Day 5 in both groups (see Supplemental Digital
Content, table suppl. 7a, http://links.lww.com/SHK/A595), so a
difference cannot be obtained. Furthermore, the wide confi-
dence intervals preclude characterizing a treatment effect.
Variability is usually high in neuropsychological testing. We
argue the tests are not sensitive enough to find a difference in
these only mildly injured animals, and that our group sizes
might have been too small for purposeful tests. For the tests of
global activity and sensorimotor integration, which are often
used and even have been developed for the assessment in the
setting of cardiac arrest (16), we might speculate that functional
recovery has occurred since neuronal injury outside the CA1
region is very mild in our model (29).
As outlined before, we have seen mild neuronal injury
compared to similar models of cardiac arrest. For example,
Bru¨cken’s group used a 7min cardiac arrest time, adding up the
time to ROSC results in a combined no-flow/low-flow time of
645 s (30). Boettiger’s group usually uses 6 min of CA, and
resuscitations take about 160 s, adding up to 520 s (16), which is
less than our 650 s in the 10 min cardiac arrest groups. The
postresuscitation care is similar to what is done by Bru¨cken
(ventilation for 4–5 h), but early weaning from ventilation is
usually done in Boettiger’s experiments. Both groups use
electrical currency to induce ventricular fibrillation, which
might result in prolonged myocardial stunning and cardiac
failure (31). This might explain the relatively low postresusci-
tation mortality in our experiments, which precluded survival
analysis in series 1 and resulted in a probably underpowered
‘‘false negative’’ result in survival analysis in series 2. In our
model, cardiac arrest is induced with potassium and esmolol, a
short-acting b-receptor antagonist. Neuroprotective properties
of beta-blocking substances have been discussed (32), but
esmolol is relatively short-living and should not cross the
bloodbrain barrier. We think the neuroprotective effect of
esmolol is small, if ever, but we cannot exclude an effect.
This is the first in-vivo study performed so far on pifithrin-m
administration in animals that underwent cardiac arrest and
resuscitation. The main strength of our study is that we
employed a reproducible cardiac arrest model, with standar-
dized post-cardiac arrest conditions. A limitation of our study is
the wide variability of the results, particularly in neurobeha-
vioral tests. The significant reduction of the cell layer breadth
of the CA1 segment in the pifithrin-m group (table suppl. 4,
http://links.lww.com/SHK/A595) must be interpreted cau-
tiously because the borders of the CA1 segment is difficult
to delineate in the u-shaped hippocampus and cannot be stand-
ardized by simple manners. We therefore decided to abstain
from this examination in the second series.
The results in the CV staining did not reach statistical
significance, which is unexpected, given the results of
the Fluoro Jade B staining. We think this is due to two
circumstances. First, determination of damage by cresyl violet
staining, which is a non-specific stain, relies on purely morpho-
logical criteria (shrunken appearance and condensed nucleus) and
is not firm, compared the easily identifiable degenerating neurons
in the FJB staining. Second, since hippocampal damage after
ischemic event is an evolvingmechanism, assessment of neuronal
damage with the CV staining based on morphological criteria is
likely to detect cell death in a more advanced stage. In contrast,
FluoroJade staining already labels damaged neurons with a rather
intact morphology. Therefore, results are likely to differ between
both methods, depending on the time at which brains were
harvested after the insult. Such differences between staining
methods have been reported previously, although in different
models (33, 34). The trend in the CV staining shows in the same
direction as the FJB staining, which supports our results.
The current literature exhibits insufficient knowledge of
dose, timing, duration, and diluents of pifithrin-m. In our first
series, we have administered 8mg/kg of pifithrin-m intra-
peritonally, which is based on the experiment of Nijboer
et al. (10). Nijboer has used two different doses of pifithrin-m
(2 and 8mg/kg), the lower dose had no effect. To circumvent
the insecurity of intraperitoneal drug administration, we have
used an intravenous formulation in the second series. We
have used a dose of 12mg/kg of pifithrin-m in ethanol
(instead of DSMO) as a starting point, but did not see a
dose effect. This has to be explored by further animal studies.
Furthermore, the effect of pifithrin-m on systemic inflam-
matory response is not yet known. In addition, since per-
manent damage or dysfunctional p53 invariably leads to
cancer, and other untoward effects of temporary blockade
of p53 might arise (e.g., adverse remodeling of myocardial
infarct zone even though reduced myocyte apoptosis (26))
the long-term effects of temporary p53 inhibition need to be
studied in the future.
CONCLUSION
After cardiac arrest and resuscitation, temporary inhibition
of the neuronal apoptosis via the mitochondrial pathway with
the small molecule pifithrin-m reduces neuronal damage in the
brain’s most vulnerable area, the hippocampus CA1 region,
compared to control. The optimal dose, route of administration,
and long-term effects of temporarily blocking apoptosis need to
be studied further.
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